271 related articles for article (PubMed ID: 24211402)
1. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
2. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
3. HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
[TBL] [Abstract][Full Text] [Related]
4. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
5. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
6. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
7. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.
Saarelainen SK; Peltonen N; Lehtimäki T; Perheentupa A; Vuento MH; Mäenpää JU
Am J Obstet Gynecol; 2013 Aug; 209(2):142.e1-6. PubMed ID: 23583212
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].
Zhang AM; Zhang P
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745
[TBL] [Abstract][Full Text] [Related]
10. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer.
Chen YL; Huang CY; Chien TY; Huang SH; Wu CJ; Ho CM
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):397-402. PubMed ID: 21806586
[TBL] [Abstract][Full Text] [Related]
11. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract][Full Text] [Related]
12. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
14. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer.
Chao A; Tang YH; Lai CH; Chang CJ; Chang SC; Wu TI; Hsueh S; Wang CJ; Chou HH; Chang TC
Gynecol Oncol; 2013 Jun; 129(3):500-4. PubMed ID: 23458702
[TBL] [Abstract][Full Text] [Related]
15. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
16. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.
Jiang T; Huang L; Zhang S
BMC Cancer; 2015 May; 15():396. PubMed ID: 25964114
[TBL] [Abstract][Full Text] [Related]
18. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
20. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
